Rothschild Investment LLC Trims Holdings in Elevance Health, Inc. $ELV

Rothschild Investment LLC lowered its position in shares of Elevance Health, Inc. (NYSE:ELV) by 54.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 335 shares of the company’s stock after selling 402 shares during the quarter. Rothschild Investment LLC’s holdings in Elevance Health were worth $130,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GLOBALT Investments LLC GA boosted its holdings in Elevance Health by 0.4% in the 1st quarter. GLOBALT Investments LLC GA now owns 6,306 shares of the company’s stock worth $2,743,000 after buying an additional 24 shares during the period. Hemington Wealth Management lifted its position in shares of Elevance Health by 13.3% in the first quarter. Hemington Wealth Management now owns 230 shares of the company’s stock valued at $100,000 after acquiring an additional 27 shares in the last quarter. Aspen Investment Management Inc boosted its stake in shares of Elevance Health by 2.6% in the first quarter. Aspen Investment Management Inc now owns 1,048 shares of the company’s stock worth $456,000 after acquiring an additional 27 shares during the period. Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its position in shares of Elevance Health by 5.3% during the first quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 600 shares of the company’s stock worth $261,000 after purchasing an additional 30 shares in the last quarter. Finally, Regatta Capital Group LLC grew its position in shares of Elevance Health by 3.0% during the second quarter. Regatta Capital Group LLC now owns 1,041 shares of the company’s stock worth $405,000 after purchasing an additional 30 shares in the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on ELV shares. The Goldman Sachs Group began coverage on Elevance Health in a research note on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 price target for the company. Sanford C. Bernstein dropped their target price on shares of Elevance Health from $445.00 to $420.00 and set an “outperform” rating for the company in a research report on Thursday, October 16th. TD Cowen lifted their price target on shares of Elevance Health from $330.00 to $380.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. JPMorgan Chase & Co. boosted their price target on shares of Elevance Health from $384.00 to $394.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 28th. Finally, Morgan Stanley raised their price objective on Elevance Health from $316.00 to $359.00 and gave the company an “equal weight” rating in a research report on Tuesday, October 14th. Twelve investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $397.33.

Elevance Health Price Performance

Elevance Health stock opened at $316.84 on Thursday. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. The firm’s fifty day moving average is $330.57 and its 200 day moving average is $339.47. The company has a market cap of $70.41 billion, a price-to-earnings ratio of 12.95, a PEG ratio of 1.23 and a beta of 0.60.

Elevance Health (NYSE:ELV) last posted its earnings results on Tuesday, October 21st. The company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.03 by $1.00. The firm had revenue of $50.09 billion for the quarter, compared to the consensus estimate of $49.26 billion. Elevance Health had a net margin of 2.84% and a return on equity of 16.17%. The business’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the previous year, the firm posted $8.37 EPS. Sell-side analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 19th. Shareholders of record on Friday, December 5th will be paid a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, December 5th. Elevance Health’s payout ratio is presently 27.96%.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.